IMV logo

IMV

IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.

3

Funding Rounds

$55.3m

Money raised

Overview

IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.

Funding

Funding series

Funding Series Analysis

The company IMV has raised a total of $55.35m in funding over 3 rounds.

Key Insights:

  • IMV Funding Round, January 2022: $750k
  • IMV Private equity, May 2020: $25.1m
  • IMV Private equity, March 2019: $29.5m
IMV logo
IMV Funding Round, January 2022 $750k
IMV logo
IMV Private equity, May 2020 $25.1m
IMV logo
IMV Private equity, March 2019 $29.5m